Adding pertuzumab to trastuzumab and taxanes in HER2 positive breast cancer

Gleeson; J.P.; Keegan; N.M.; Morris; P.G.

首页> 外文期刊>Expert opinion on biological therapy >Adding pertuzumab to trastuzumab and taxanes in HER2 positive breast cancer

【24h】

Adding pertuzumab to trastuzumab and taxanes in HER2 positive breast cancer

机译：将Pertuzumab添加到Her2阳性乳腺癌中的曲妥珠猴和紫杉烷

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Introduction: The monoclonal antibody trastuzumab has improved the median disease free and overall survival of patients with early stage breast cancer that overexpresses the human epidermal growth factor receptor 2 (HER2). Despite this advance, some patients experience cancer relapse and novel approaches are always needed. One such advance is the monoclonal antibody pertuzumab, which prevents dimerisation between members of the HER family of transmembrane glycoprotein receptors. Areas covered: In this review, the authors analyse recent research which has focused on the development of new HER2 targeting agents for HER2-positive breast cancer, particularly pertuzumab, and its addition to trastuzumab and taxanes. Expert opinion: Pertuzumab has significantly improved disease control in patients with advanced HER2 positive breast cancer when added to chemotherapy and trastuzumab. Although pertuzumab has also increased response rates in the preoperative setting, this has not yet translated into increased overall survival. The authors believe that future research should focus on improvements in novel biomarkers to select patients for new treatments.

机译：介绍：单克隆抗体曲妥珠单抗改善了早期乳腺癌患者的中位疾病和整体存活，其过表现出人表皮生长因子受体2（HER2）。尽管提前，但是一些患者经历癌症复发和新方法。一种这样的预先是单克隆抗体pertuzumab，其防止了她的跨膜糖蛋白受体的成员之间的二聚化。所涵盖的地区：在本次审查中，作者分析了最近的研究，其专注于为Her2阳性乳腺癌，特别是Pertuzumab的新HER2靶向药物的开发以及与TRASTUZIMAB和TACALEAB的添加。专家意见：当添加到化疗和曲妥珠单抗时，Pertuzumab患有先进海绵阳性乳腺癌患者的疾病控制。虽然Pertuzumab在术前设定中也增加了响应率，但这尚未转化为增加整体生存率。作者认为未来的研究应专注于新型生物标志物的改善，为患者选择新疗法。

著录项

来源
《Expert opinion on biological therapy》 |2018年第6期|共12页
作者
Gleeson; J.P.; Keegan; N.M.; Morris; P.G.;
展开▼
作者单位

Cancer Clinical Trials and Research Unit Beaumont Hospital and RCSI Dublin 9 Ireland;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类治疗学;
关键词
Breast Cancer; Dual HER2 blockade; Pertuzumab; Review; Taxanes; Trastuzumab;

机译：乳腺癌;双重HER2封锁;pertuzumab;审查;紫杉烷;曲妥珠单抗;

相似文献

外文文献
中文文献
专利

1. Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD) [J] . Toshinari Yamashita, Norikazu Masuda, Shigehira Saji, Trials . 2020,第1期

机译：Trastuzumab，Pertuzumab和Eribulin甲磺酸丁酯与曲妥珠单抗，Pertuzumab和紫罗兰作为Her2阳性，局部晚期或转移性乳腺癌的一线或二线治疗：用于随机控制，非劣势，III期的研究方案日本试验（JBCRG-M06 / Emerald）
2. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer [J] . Edith A. Perez, Sanne Lysbet de Haas, Wolfgang Eiermann, BMC Cancer . 2019,第1期

机译：肿瘤生物标志物与Marianne疗效的关系，III研究曲妥珠单抗±Pertuzumab与曲妥珠单抗加紫罗兰在Her2阳性晚期乳腺癌中的研究
3. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer [J] . Giampaolo Bianchini, Astrid Kiermaier, Giulia Valeria Bianchi, Breast Cancer Research . 2017,第1期

机译：NeoSphere研究的生物标志物分析：帕妥珠单抗，曲妥珠单抗和多西他赛与曲妥珠单抗加多西他赛，帕妥珠单抗加曲妥珠单抗或帕妥珠单抗加多西他赛用于HER2阳性乳腺癌的新辅助治疗
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Trastuzumab pertuzumab and eribulin mesylate versus trastuzumab pertuzumab and a taxane as a first-line or second-line treatment for HER2-positive locally advanced or metastatic breast cancer: study protocol for a randomized controlled non-inferiority phase III trial in Japan (JBCRG-M06/EMERALD) [O] . Toshinari Yamashita, Norikazu Masuda, Shigehira Saji, 2020

机译：曲妥珠单抗帕妥珠单抗和甲磺酸艾瑞布林与曲妥珠单抗帕妥珠单抗和紫杉烷作为一线或二线治疗HER2阳性局部晚期或转移性乳腺癌的一线或二线治疗：III期随机对照非劣效性的研究方案在日本试用（JBCRG-M06 / EMERALD）
7. Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD) [O] . Toshinari Yamashita, Norikazu Masuda, Shigehira Saji, 2020

机译：校正至：Trastuzumab，Pertuzumab和Eribulin甲蛋白与曲妥珠单抗，Pertuzumab和紫杉烷作为Her2阳性，局部晚期或转移性乳腺癌的一线或二线治疗：用于随机控制，非劣势的研究方案，日本第三阶段试验（JBCRG-M06 / Emerald）

Adding pertuzumab to trastuzumab and taxanes in HER2 positive breast cancer

摘要

著录项

相似文献

相关主题

期刊订阅